Chattem CHTT
-
New Product Sales Boost Sanofi's 3Q Despite Generic Competition to Lovenox
… operationally by 2% year over year, largely because of new generic competition to anticoagulant drug Lovenox. The acquisition of Chattem added 1 percentage point to growth in the quarter. Earnings per share decreased 2% versus the prior-year period at constant …
-
Upside to Sanofi's Genzyme Bid
… pharma in emerging markets, and has moved to expand into over-the-counter health-care products with the acquisition of Chattem . Other than some potential marketing synergies between Sanofi's cardiovascular sales force and Genzyme's late-stage …
-
Genzyme a Logical Target, But Weak Strategic Fit with Sanofi
… pharma in emerging markets, and has moved to expand into over-the-counter health-care products with the acquisition of Chattem . Other than some potential marketing synergies between Sanofi's cardiovascular sales force and Genzyme's late-stage …
-
ARBFX Arbitrage R Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… options on target stocks to capture premium income, a tactic that increased annualized returns on deals such as the Chattem CHTT /Sanofi-Aventis SNY and the ExxonMobil XOM/XTO XTO mergers by 1%-2%. Management can also improve returns by …
-
Behind the Bullish Take on Our Top Pharma Pick… companies trying to branch out a little bit to get more diversified, get less volatility. Also, with the recent acquisition of Chattem by Sanofi-Aventis, that's another example where you see a branded pharmaceutical firm reaching out of the branded drug …
get more diversified, get less volatility. Also, with the recent acquisition of Chattem by Sanofi-Aventis, that's another example where you see a branded pharmaceutical firm reaching out of the branded drug space and try to -
Novartis Presents a Bullish Options Opportunity
The Opportunity Following on the heels of the Sanofi acquisition of a former OptionInvestor recommendation , Chattem , another European drug giant, Novartis NVS announced its intention to take full control of eye-care leader Alcon ACL. Novartis …
-
Acquisition a Good Deal for Chattem
… increasing our fair value estimate for Chattem CHTT significantly, to $93.50 per ..... approximately a 34% premium to Chattem 's closing price Dec. 18 and 44 ..... valued the shares. The deal accords Chattem a multiple of approximately 12 times …
-
Sanofi Acquires Chattem
… Sanofi SNY announced it will acquire Chattem CHTT for $1.9 billion in a friendly all-cash deal that gives Chattem shareholders a 34% premium to where ..... that Sanofi might be overpaying for Chattem , considering our fair value estimate …
-
Niche Consumer Player Chattem Revitalizes BrandsErik Kobayashi-Solomon and Erin Swanson hash out how niche player Chattem has maintained its impressive operating margins despite competition from giants like Proctor and Gamble.
-
Chattem Reports Solid 2Q
Chattem CHTT reported solid second-quarter results ..... cautious of the numerous head winds that Chattem continues to face--namely soft consumer ..... even more impressive considering that Chattem has dramatically increased its promotional …